<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801930</url>
  </required_header>
  <id_info>
    <org_study_id>293-12-001</org_study_id>
    <nct_id>NCT01801930</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer</brief_title>
  <official_title>A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed
      Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of dose limiting toxicity (DLT) will be evaluated in cohorts of six patients by
      starting OCV-C02 administration at dose level 1 (OCV-103 and OCV-104 at 0.3 mg each),
      increasing the dose to dose level 2 (at 1 mg each), level 3 (at 3 mg each), and then up to
      dose level 4 (at 6 mg each). Once-weekly administration will be repeated four times in each
      treatment cycle, and the incidence of DLT from Day 1 to Day 29 will be evaluated.

      At the end of Cycle 1, patients who wish to continue OCV-C02 treatment and have provided
      their written consent will be permitted to continue participation in the trial using the same
      dosing schedule for each subsequent cycle as that for Cycle 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>1 Month (29Day)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>September 2014</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>September 2014</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-response</measure>
    <time_frame>29 days, September 2014</time_frame>
    <description>DTH reactions，CTL Measurement，Blood Regulatory T Cell Measurement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>0.3 mg of each</description>
    <arm_group_label>Dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>1 mg of each</description>
    <arm_group_label>Dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>3 mg of each</description>
    <arm_group_label>Dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-103 and OCV-104</intervention_name>
    <description>6 mg of each</description>
    <arm_group_label>Dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have human leukocyte antigen (HLA)-A*24:02

          -  Patients who have histologically-confirmed colorectal cancer (adenocarcinoma)

          -  Patients with advanced or relapsed colorectal cancer who are refractory or intolerant
             to standard chemotherapy

          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of
             0 to 1 at the time of enrollment in the trial.

        Exclusion Criteria:

          -  Patients who are HIV antibody test positive

          -  Patients with an active infection

          -  Patients who have or are suspected to have CNS metastasis of colon cancer (such as
             metastatis of the brain)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junichi Hashimoto, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCV-C02</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Antigen specific cancer immunotherapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

